glp 1 triple agonist Upcoming wave of hormone-based therapies set to change field of diabetes, obesity care Beyond GLP-1: Retatrutide's triple-agonist mechanism

But the BBB tells a parallel story of billing confusion, aggressive retention, and refund denials that cant be dismissed

doi: 10.1210/endo.133.1.8319572 47 DamholtABBuchanAMKofodH

[DOI] [PubMed] [Google Scholar] 588.Xu E., Kumar M., Zhang Y., Ju W., Obata T., Zhang N

DISCLOSURES ABJ has received honoraria for speaking from Abbott, AstraZeneca, Boehringer Ingelheim, Dexcom, Eli Lilly, Janssen, Merck, Novo Nordisk and Sanofi, and has been involved in advisory boards for Abbott, AstraZeneca, Boehringer Ingelheim, Dexcom, Eli Lilly, Novo Nordisk and Sanofi

In addition, GLP-1-specific tailored treatment is just around the corner